Belgium· BE-AMP-SAM435942-00
Perjeta 420 mg
A pertuzumab product containing pertuzumab, registered in Belgium by Roche Registration. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Pertuzumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD02 (pertuzumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Pertuzumab · ATC L01FD02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Pertuzumab
- Manufacturer
- Roche Registration
- Country
- Belgium (BE)
- ATC code
- L01FD02
- ATC class
- Pertuzumab
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
- be_apb3019890
- be_apb7707466
- be_apb3666260
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for pertuzumab.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pertuzumab · interactions on record
2 records
- 2 moderate
Most severe, free to view
- IdelalisibL01EM01moderate
- IdelalisibL01XX47moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pertuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPerjeta2care4 ApS
- CzechiaPERJETARoche Registration GmbH, Grenzach-Wyhlen
- IrelandPerjeta 420 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandPerjetaRoche Registration GmbH*
- SwedenPerjeta 420 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- PolandPoherdyN.V. Organon
- SpainPERJETA 420 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United KingdomPerjeta 420mg/14ml concentrate for solution for infusion vialsOriginalis B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Perjeta, Poherdy
- Liechtenstein · Perjeta, Poherdy
- Norway · Perjeta, Poherdy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8ffff26c-83b3-4cb0-913b-50307fed2c88 GET /v1/drugs/8ffff26c-83b3-4cb0-913b-50307fed2c88?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Perjeta 420 mg",
"name_fr": "Perjeta 420 mg",
"name_nl": "Perjeta 420 mg",
"amp_code": "SAM435942-00",
"strengths": [
"30.0000"
],
"pack_count": 3,
"substances": [
"Pertuzumab",
"Sucrose",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Pertuzumab",
"authorisation_numbers": [
"EU/1/13/813/001"
]
}See everything about pertuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.